CJC-1295 and Ipamorelin: Research Overview

CJC-1295 and ipamorelin are frequently discussed together because both act on the growth hormone axis, but they do so through different receptors. CJC-1295 is a modified analog of GHRH(1-29) carrying amino acid substitutions for stability; in its DAC (drug affinity complex) form it also carries a conjugate that binds serum albumin, substantially extending circulating half-life. PubChem lists the DAC-conjugated form with the formula C165H269N47O46 and a molecular weight of approximately 3647.2 g/mol.

Ipamorelin is a pentapeptide with the published sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, formula C38H49N9O5 and molecular weight approximately 711.9 g/mol. It is described in the literature as a selective agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a (GHS-R1a).

The key human study is Teichman et al., published in the Journal of Clinical Endocrinology & Metabolism in 2006. In healthy adults, single injections of CJC-1295(DAC) produced sustained, dose-dependent elevations in growth hormone and IGF-1, with effects observed over a period of days rather than hours — a direct consequence of the albumin-binding design.

That study is the strongest human pharmacodynamic evidence for the compound. It characterizes what happens to GH and IGF-1 concentrations; it is not an outcome trial and does not establish safety or efficacy for any use.

Ipamorelin was introduced in a 1998 European Journal of Endocrinology paper by Raun and colleagues describing it as the first selective growth hormone secretagogue. In animal pharmacology and early human characterization, ipamorelin stimulated GH release with comparatively little effect on ACTH, cortisol, and prolactin — the selectivity that distinguished it from earlier secretagogues.

That selectivity claim is the compound's defining published characteristic and is the reason it appears so often in GH-axis research discussions.

The combined CJC-1295 plus ipamorelin regimen — engaging the GHRH receptor and the ghrelin receptor at the same time — is widely discussed but thinly evidenced. Recent review literature covering performance-enhancing peptides, injectable peptides in sports medicine, and therapeutic peptides in endocrine contexts confirms the individual mechanistic findings while noting that the fixed combination itself lacks dedicated controlled human trials, systematic safety data, and regulatory approval.

Those reviews discuss the combination largely in the context of off-label and self-administered use and anti-doping concerns. For a research audience the practical takeaway is that combination effects should be treated as an open question, not as an established pharmacological profile.

Neither CJC-1295 nor ipamorelin is FDA-approved for any indication. Both are supplied by North Summit Labs strictly as laboratory research materials.

Blended lyophilized material is handled like any other peptide preparation: sealed and dry until use, equilibrated before opening, reconstituted with an appropriate solvent, aliquoted to avoid repeated freeze-thaw cycling, and kept cold and protected from light in solution. Because this is a blend, the certificate for the lot documents what was analyzed — read it against the vial label before use.

This monograph summarizes published scientific literature for educational and reference purposes only. It is not medical, veterinary, clinical, or dosing guidance, and nothing here should be read as a claim that this compound is safe, effective, or approved for use in humans or animals.

Material supplied by North Summit Labs is intended strictly for in-vitro laboratory research by qualified professionals. It is not a drug, supplement, food, cosmetic, or medical device, and it is not for human or animal consumption. Investigators are responsible for complying with their own institutional oversight, biosafety, and legal requirements.